 |
|
|
| |
Safety and Efficacy of Peginterferon Lambda-1a (Lambda) Compared With Peginterferon Alfa-2a (Alfa-2a) in HCV-Infected Patients (G1/2/3) With Compensated Cirrhosis: EMERGE Phase 2B Efficacy and Safety Results Through Week 12
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 201 SF
Rodriguez-Torres M,1 Hillson J,2 Bacon B,3 Box T,4 Hassanein T,5 Greenbloom S,6 Lawitz E,7 Vargas H,8 Vierling J,9 Horga A,1 Ramos E,2 Fontana D,2 Freeman J,2 Gray T,2 Bittner R,2 Xu D,2 Ishak L,2 Lopez-Talavera JC,10 for the EMERGE Study Group
1Fundación de Investigación Puerto Rico, San Juan, Puerto Rico; 2Zymogenetics/BMS, Seattle, WA; 3Saint Louis University, St Louis, MO; 4University of Utah, Salt Lake City, UT; 5SCTI Research Foundation, Coronado, CA; 6Toronto Digestive Disease Associates, Vaughan, ON, Canada; 7Alamo Medical Research, San Antonio, TX; 8Mayo Clinic, Phoenix, AZ; 9Baylor College of Medicine, Houston, TX; 10Bristol Myers Squibb, Wallingford, CT
|
| |
|
|
|
|
|
